natgillin/translations-raw huggingface dataset:
Serious ocular adverse reactions in the study eye related to the injection procedure have occurred in less than 1 in 1,900 intravitreal injections with Eylea and included blindness, endophthalmitis, retinal detachment, cataract traumatic, cataract, vitreous haemorrhage, vitreous detachment, and intraocular pressure increased (see section 4.4). 
Resni očesni neželeni učinki, povezani s postopkom injiciranja, ki so se pojavili v zdravljenem očesu, pri manj kot 1 od 1.900 intravitrealnih injekcij zdravila Eylea, so vključevali slepoto, endoftalmitis, odstop mrežnice, travmatsko katarakto, katarakto, krvavitev v steklovino, odstop steklovine in povišan intraokularni tlak (glejte poglavje 4.4).
• The dose should be withheld within the previous or next 28 days in the event of a performed or planned intraocular surgery. 
• Z zdravljenjem je treba prenehati 28 dni pred načrtovano intraokularno operacijo in se ga lahko nadaljuje 28. dan po opravljeni intraokularni operaciji.
• What are the steps following treatment with Eylea 
• koraki, ki bodo sledili po zdravljenju z zdravilom Eylea
The use of Eylea in children or adolescents under 18 has not been studied because wet AMD, CRVO, BRVO, DME and myopic CNV occur mainly in adults. 
Uporabe zdravila Eylea pri otrocih in mladostnikih, starih manj kot 18 let, niso preučevali, ker se vlažna starostna degeneracija rumene pege, makularni edem, ki nastane kot posledica zapore centralne mrežnične vene ali veje mrežnične vene, diabetični makularni edem in miopična CNV pojavljajo predvsem pri odraslih.
Absent or irregular menses associated with alterations in female reproductive hormone levels and changes in sperm morphology and motility were observed at all dose levels. 
Pri vseh odmerkih so opazili izostanek ali neredno menstruacijo, povezano s spremembo vrednosti ženskih spolnih hormonov, in spremenjeno morfologijo in gibljivost spermijev.
Post-authorisation efficacy study (PAES) To perform an interventional post-authorisation efficacy study in patients with diabetic macular oedema with the primary objective of comparing, after the first initial year of Eylea treatment, the standard regime of injections every 8 weeks with alternative treatment regimens, i.e. extended treatment intervals based on visual and anatomic outcomes (PRN and treat-and-extend). 
Post-avtorizacijska študija učinkovitosti (PAES) Izvesti intervencijsko post-avtorizacijsko študijo učinkovitosti pri bolnikih z diabetičnim makularnim edemom, katere primarni cilj bo primerjati, po začetnem letu zdravljenja z zdravilom Eylea, standardni režim injiciranja vsakih 8 tednov z alternativnimi režimi zdravljenja tj. podaljšani intervali med injekcijami glede na oceno ostrine vida in anatomski izgled rumene pege (PRN in »zdraviti in podaljšati«)
You will start your treatment with a series of monthly Eylea injections. 
Zdravljenje boste začeli s serijo injekcij zdravila Eylea, ki jih boste prejemali mesečno.
Furthermore, in the 4-week adjustment group 40.7% of patients were extended to 16 week intervals. 
Pri 40,7 % bolnikov je bil v skupini, ki so ji interval med injekcijami podaljševali po 4 tedne, interval podaljšan na 16 tednov.
The MAH has agreed to provide EU Educational Material for Eylea. 
Imetnik dovoljenja za promet se strinja, da se za zdravilo Eylea pripravi izobraževalno gradivo.
This increased incidence was comparable between patients treated with ranibizumab and Eylea. 
Ta povečana pogostnost je bila primerljiva med bolniki, ki so prejemali ranibizumab in zdravilo Eylea.
To deter the introduction of air, ensure the bevel of the filter needle is submerged into the liquid. 
Da preprečite vnos zraka, zagotovite, da je poševni del filtrirne igle potopljen v tekočino.
Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition. 
Arterijski trombembolični dogodki so neželeni učinki, ki so morda povezani s sistemskim zaviranjem VEGF.
Patient ages ranged from 42 to 94 years with a mean of 65 years. 
Bolniki so bili stari od 42 do 94 let, v povprečju 65 let.
The fixed regimen for Eylea rescue was three times Eylea 2mg every 4 weeks followed by injections every 8 weeks. 
Fiksen režim za rešilno zdravljenje z zdravilom Eylea je bil trikrat zdravilo Eylea 2 mg vsake 4 tedne, nato pa vsakih 8 tednov.
Some of these may be serious and include blindness, a serious infection or inflammation inside the eye (endophthalmitis), detachment, tear or bleeding of the light-sensitive layer at the back of the eye (retinal detachment or tear), clouding of the lens (cataract), bleeding in the eye (vitreous haemorrhage), detachment of the gel-like substance inside the eye from the retina (vitreous detachment) and increase of pressure inside the eye, see section 2. 
Nekateri med njimi so lahko resni in vključujejo slepoto, resne okužbe in vnetja znotraj očesa (endoftalmitis), odstop, raztrganine ali krvavitve v na svetlobo občutljivo plast v zadnjem delu očesa (odstop ali raztrganine mrežnice), motnjavo leče (katarakta), krvavitve v očesu (krvavitve v steklovino), odstop gelu podobne snovi znotraj očesa od mrežnice (odstop steklovine) in povišanje očesnega tlaka, glejte poglavje 2.
The systemic exposure based on Cmax and AUC for free aflibercept were approximately 200and 700-fold higher, respectively, when compared to corresponding values observed in humans after an intravitreal dose of 2 mg. At the No Observed Adverse Effect Level (NOAEL) of 0.5 mg/eye in monkeys the systemic exposure was 42- and 56-fold higher based on Cmax and AUC, respectively. 
Sistemska izpostavljenost za prosti aflibercept glede na Cmax in AUC je bila približno 200-krat oziroma 700-krat večja v primerjavi z ustreznimi vrednostmi, ki so jih opazili pri ljudeh, po intravitrealnem odmerku 2 mg. Glede na NOAEL (No Observed Adverse Effect Level) je bila sistemska izpostavljenost pri opicah pri odmerku 0,5 mg/oko 42-krat večja glede na Cmax oziroma 56krat večja glede na AUC.
Your doctor will monitor this after each injection. 
Zdravnik vam bo po vsaki injekciji izmeril očesni tlak.
• visual impairment due to diabetic macular oedema (DME) (see section 5.1), 
• okvare vida zaradi diabetičnega makularnega edema (DME - Diabetic Macular Oedema) (glejte poglavje 5.1),
Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of aflibercept (see section 4.4). 
Ženske v rodni dobi morajo med zdravljenjem in še vsaj 3 mesece po zadnji intravitrealni injekciji aflibercepta uporabljati učinkovito kontracepcijo (glejte poglavje 4.4).
Mean Change in Visual Acuity from Baseline to Week 96 for the Combined Data from the View1 and View2 Studies 
Povprečna sprememba ostrine vida glede na izhodiščne vrednosti do 96. tedna za združene podatke iz študij VIEW1 in VIEW2
Post-authorisation efficacy study (PAES) To perform a post-authorisation randomised study in patients with neovascular (wet) AMD with the primary objective of comparing the standard regime of injections every 8 weeks with a reactive regimen based on visual and anatomic outcomes, based on a CHMP approved protocol. 
Post-avtorizacijska študija učinkovitosti (PAES) Izvesti post-autorizacijsko randomizirano študijo pri bolnikih z neovaskularno (vlažno) AMD, katere primarni cilj bo primerjati standardni režim injiciranja vsakih 8 tednov z režimom glede na oceno ostrine vida in anatomski izgled rumene pege, v skladu s protokolom, odobrenim s strani CHMP
In the VIBRANT study, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters in BCVA at week 24 compared to baseline and the Eylea group was superior to laser control. 
V študiji VIBRANT je bil primarni cilj učinkovitosti delež bolnikov, ki so pridobili vsaj 15 črk BCVA v 24. tednu v primerjavi z izhodiščnimi vrednostmi in zdravljenje z zdravilom Eylea je bilo superiorno v primerjavi s kontrolno skupino z laserskim zdravljenjem.
The schedule for monitoring should therefore be determined by the treating physician and may be more frequent than the schedule of injections. 
Lečeči zdravnik mora zato določiti načrt spremljanja bolnika; pregledi so lahko pogostejši kot je načrtovano injiciranje zdravila.
• Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of aflibercept (see section 4.6). 
• Ženske v rodni dobi morajo med zdravljenjem in še vsaj 3 mesece po zadnji intravitrealni injekciji aflibercepta uporabljati učinkovito kontracepcijo (glejte poglavje 4.6).
In myopic CNV there is no experience with Eylea in the treatment of non-Asian patients, patients who have previously undergone treatment for myopic CNV, and patients with extrafoveal lesions. 
Izkušenj z zdravljenjem miopične CNV z zdravilom Eylea pri neazijskih bolnikih, bolnikih, ki so že bili zdravljeni zaradi miopične CNV, in bolnikih z lezijami zunaj fovee (ekstrafovealne lezije), ni.
After the first 12 months of treatment with Eylea, the treatment interval may be extended based on your doctor's examination. 
Glede na izvid zdravniškega pregleda pa se lahko po prvih 12 mesecih zdravljenja z zdravilom Eylea interval med injekcijami podaljša.
For the intravitreal injection, a 30 G x ½ inch injection needle should be used. 
Za intravitrealno injekcijo je treba uporabiti injekcijsko iglo 30 G x 12,7 mm.
mean B,C,E 
D,C,E
• Patient information packs 
• paket izobraževalnih gradiv za bolnika
In the VIVIDDME and the VISTADME studies, a statistically significant greater mean decrease in CRT from baseline to week 52 was observed in patients treated with Eylea than with the laser control,192.4 and -183.1 microns for the 2Q8 Eylea groups and -66.2 and -73.3 microns for the control groups, respectively. 
V študijah VIVIDDME in VISTADME so opazili statistično značilno večje povprečno zmanjšanje CRT glede na izhodiščne vrednosti do 52. tedna v skupinah, ki so prejemale zdravilo Eylea kot v kontrolnih skupinah z laserskim zdravljenjem (-192,4 oziroma -183,1 mikronov v skupinah, ki so prejemale zdravilo Eylea 2Q8, ter -66,2 oziroma -73,3 mikronov v kontrolnih skupinah).
Eylea should not be used during pregnancy unless the potential benefit outweighs the potential risk to the unborn child. 
Zdravila Eylea se ne sme uporabljati med nosečnostjo, razen če so možne koristi večje od možnega tveganja za še nerojenega otroka.
Other medicines and Eylea Tell your doctor if you are using, have recently used or might use any other medicines. 
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Figure 3: Mean Change in BCVA as Measured by ETDRS Letter Score from Baseline to Week 52 in VIBRANT Study 
Slika 3: Povprečna sprememba BCVA, ocenjena z ETDRS tablicami, glede na izhodiščne vrednosti do 52. tedna v študiji VIBRANT
Patients were randomly assigned in a 3:1 ratio to receive either 2 mg Eylea intravitreally or sham injections administered once at study start with additional injections given monthly in case of disease persistence or recurrence until week 24, when the primary endpoint was assessed. 
Bolnike so naključno razporedili v razmerju 3:1 v skupino, ki je prejela intravitrealno injekcijo 2 mg zdravila Eylea ali injekcijo placeba na začetku študije, dodatne injekcije pa so prejeli enkrat mesečno do 24. tedna v primeru, da je bolezen vztrajala ali se ponovila.
Attach the 18 G, 5-micron filter needle supplied in the carton to a 1-ml sterile, Luer-lock syringe. 
Pritrdite 5-mikronsko filtrirno iglo 18 G, priloženo v škatli, na sterilno 1-ml Luer Lock brizgo.
• Key signs and symptoms of serious adverse events including endophthalmitis, intraocular pressure increased, retinal pigment epithelial tear and cataract 
• ključne znake in simptome resnih neželenih učinkov, vključno z endoftalmitisom, povišanim intraokularnim tlakom, zatrganjem pigmentnega epitelija mrežnice in katarakto
If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. 
Če se glede na oceno ostrine vida in/ali anatomski izgled rumene pege stanje poslabša, je treba interval med injekcijami ustrezno skrajšati.
VEGF levels are elevated in response causing the leakage of fluid into the retina and thereby causing a swelling of the macula, (the portion of the retina responsible for fine vision), which is called macular oedema. 
Zaradi iztekanja tekočine v mrežnico se povečajo vrednosti VEGF v krvi, kar povzroči oteklino rumene pege (del mrežnice odgovoren za ostrino vida), kar se imenuje makularni edem.
Instructions for use of pre-filled syringe: 
Navodilo za uporabo napolnjene injekcijske brizge
Patient ages ranged from 27 to 83 years with a mean of 58 years. 
Bolniki so bili stari od 27 do 83 let, v povprečju 58 let.
A secondary efficacy variable was change in visual acuity at week 24 compared to baseline. 
Spremenljivka sekundarne učinkovitosti je bila sprememba v ostrini vida v 24. tednu v primerjavi z izhodiščnimi vrednostmi.
Delivers a single dose of 2 mg/0.05 ml. 
Za enkratni odmerek 2 mg/0,05 ml.
Diabetic macular oedema is a swelling of the retina occurring in patients with diabetes due to leaking of fluid from blood vessels within the macula. 
Diabetični makularni edem je oteklina mrežnice, ki se pojavi pri bolnikih s sladkorno boleznijo zaradi iztekanja tekočine iz krvnih žil v rumeni pegi.
Eylea is not recommended during breast-feeding. 
Uporabe zdravila Eylea se ne priporoča med dojenjem.
There is no requirement for monitoring between injections. 
Med posameznimi injekcijami spremljanje bolnikov ni potrebno.
Patient ages ranged from 49 to 99 years with a mean of 76 years. 
Bolniki so bili stari od 49 do 99 let, v povprečju 76 let.
Active Control (laser)/Eylea 2mgE) 
aktivna kontrola (lasersko zdravljenje) / zdravilo Eylea 2mgE (N = 90)
ETDRS: Early Treatment Diabetic Retinopathy Study 
BCVA: najboljša korigirana ostrina vida (Best Corrected Visual Acuity) ETDRS: študija zgodnjega zdravljenja diabetične retinopatije (Early Treatment Diabetic Retinopathy Study)
In patients treated with Eylea (one injection per month for three consecutive months, followed by one injection every 2 months), central retinal thickness [CRT] decreased soon after treatment initiation, and the mean CNV lesion size was reduced, consistent with the results seen with ranibizumab 0.5 mg every month. 
Pri bolnikih, zdravljenih z zdravilom Eylea (ena injekcija na mesec, tri zaporedne mesece, nato pa ena injekcija vsaka dva meseca), se je centralna debelina mrežnice (CRT - Central Retinal Tickness) zmanjšala kmalu po uvedbi zdravljenja in tudi povprečna velikost CNV lezije se je zmanjšala, kar je bilo v skladu z izsledki, vidnimi pri bolnikih, ki so prejemali ranibizumab 0,5 mg vsak mesec.
Treatment may then be continued with a treat-and-extend regimen with gradually increased treatment intervals to maintain stable visual and/or anatomic outcomes, however there are insufficient data to conclude on the length of these intervals. 
Zdravljenje bo morda treba nadaljevati z režimom »zdravi in podaljšaj«, tj. s postopnim podaljševanjem intervala med injekcijami, da se ohrani stabilen vid in/ali anatomski izgled rumene pege, čeprav ni dovolj podatkov za odločitev glede dolžine intervalov.
Week 96 Week 52 
96. teden 52. teden
Patients with myopic CNV will be treated with one single injection. 
Bolnikom z miopično horoidalno neovaskularizacijo bo zdravilo injicirano enkrat.
A After treatment initiation with 5 monthly injections 
Po 5 začetnih mesečnih injekcijah
Always discuss any suspected side effects with your doctor. 
Pri sumu na neželene učinke se vedno posvetujte z zdravnikom.
At week 16, patients were randomised 1:1 into two treatment groups: 1) Eylea treat-and-extend with 2-week adjustments and 2) Eylea treat-and-extend with 4-week adjustments. 
V 16. tednu so bili bolniki randomizirani (v razmerju 1:1) v dve skupini zdravljenja: 1) skupina zdravljena z zdravilom Eylea, ki so ji interval med injekcijami spreminjali po 2-tedna in 2) skupina zdravljena z zdravilom Eylea, ki so ji interval med injekcijami spreminjali po 4-tedne.
Based on pre-specified criteria, patients in the laser group could receive rescue treatment with Eylea 2mg from week 24, administered every 4 weeks for 3 months followed by every 8 weeks. 
Glede na vnaprej določene kriterije so bolniki v kontrolni skupini z laserskim zdravljenjem, lahko od 24. tedna prejeli rešilno zdravljenje z zdravilom Eylea v odmerku 2 mg, vsake 4 tedne, tri zaporedne mesece, nato pa so nadaljevali z injekcijami vsakih 8 tednov.
In these clinical studies, approximately 89% (1,616/1,817) of the patients randomised to treatment with Eylea were 65 years of age or older, and approximately 63% (1,139/1,817) were 75 years of age or older. 
V teh kliničnih študijah je bilo približno 89 % (1.616/1.817) bolnikov, randomiziranih v skupino, ki je prejemala zdravilo Eylea, starih 65 let ali več, približno 63 % (1.139/1.817) jih je bilo starih 75 let ali več.
At week 52, patients in the treat-and-extend arm with 2-week adjustments gained a mean of 9.0 letters from baseline as compared to 8.4 letters for those in the 4-week adjustment group [LS mean difference in letters (95% CI): -0.4 (-3.8,3.0), ANCOVA]. 
V 52. tednu so bolniki v skupini zdravljeni z režimom »zdravi in podaljšaj« pridobili v povprečju 9,0 črk od izhodiščne vrednosti v skupini, ki so ji interval med injekcijami podaljševali po 2 tedna oziroma 8,4 črk v skupini, ki so ji interval med injekcijami podaljševali po 4 tedne [LS razlika v črkah (95 % CI): -0,4 (-3,8; 3,0), ANCOVA].
To remove the syringe cap, hold the syringe in one hand while using the other hand to grasp the syringe cap with the thumb and fore finger. 
Če želite odstraniti zaščitno zaporko z brizge, brizgo držite z eno roko in s kazalcem in palcem druge roke primite zaščitno zaporko.
The magnitude of these changes was similar to that seen in published studies, which corresponded to a 15-letter gain in Best Corrected Visual Acuity (BCVA). 
Obseg teh sprememb je bil podoben kot v objavljenih študijah in ustreza pridobitvi 15 črk BCVA (najboljša korigirana ostrina vida).
The recommended dose is 2 mg aflibercept (50 microlitres). 
Priporočeni odmerek je 2 mg aflibercepta (50 mikrolitrov).
• Treatment should be withheld in patients with rhegmatogenous retinal detachment or stage 3 or 4 macular holes. 
• Pri bolnikih z regmatogenim odstopom mrežnice ali foramnom makule III. ali IV. stopnje je treba z zdravljenjem prenehati.
If a dose of Eylea is missed 
Če ste izpustili odmerek zdravila Eylea
In the event of either being observed, discard the medicinal product. 
Če opazite kar koli od naštetega, je treba zdravilo zavreči.
Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. 
Takoj po intravitrealni injekciji je treba preveriti intraokularni tlak.
At baseline, the proportion of perfused patients in the Eylea and laser groups was 60% and 68%, respectively. 
Na začetku je bil delež perfundiranih bolnikov v skupini, ki je prejemala zdravilo Eylea, in v kontrolni skupini z laserskim zdravljenjem, 60 % oziroma 68 %.
After the first 12 months of treatment with Eylea, and based on visual and/or anatomic outcomes, the treatment interval may be extended, such as with a treat-and-extend dosing regimen, where the treatment intervals are gradually increased to maintain stable visual and/or anatomic outcomes; however there are insufficient data to conclude on the length of these intervals. 
Po prvih 12 mesecih zdravljenja z zdravilom Eylea in glede na oceno ostrine vida in/ali anatomski izgled rumene pege, se lahko interval med injekcijami podaljša, na primer z režimom odmerjanja »zdravi in podaljšaj«, kjer se intervali med injekcijami postopoma podaljšujejo, da se ohrani stabilna ostrina vida in/ali anatomski izgled rumene pege, čeprav ni dovolj podatkov za odločitev o dolžini teh intervalov.
All patients received monthly doses of Eylea 2 mg for 3 months, followed by one injection after a further 2 month interval. 
Vsi bolniki so prejemali eno injekcijo zdravila Eylea 2 mg na mesec, tri zaporedne mesece, nato pa še eno injekcijo po dveh mesecih.
G) In GALILEO study, both control group and Eylea 2mg patients received Eylea 2 mg on an as-needed basis every 8 weeks starting from week 52 to week 68; patients had mandatory visits every 8 weeks. 
V študiji GALILEO so bolniki v kontrolni skupini in bolniki zdravljeni z zdravilom Eylea 2 mg, od 52. do 68. tedna, prejemali zdravilo Eylea 2 mg glede na potrebe vsakih 8 tednov; bolniki so imeli obvezne preglede vsakih 8 tednov.
Pregnancy and breast-feeding - Women of childbearing potential have to use effective contraception during treatment and for at least three further months after the last injection of Eylea. 
Nosečnost in dojenje - Ženske v rodni dobi morajo med zdravljenjem in še vsaj tri mesece po zadnji injekciji zdravila
• Key signs and symptoms of intravitreal injection related adverse events including endophthalmitis, increased intraocular pressure, retinal pigment epithelial tear and cataract 
• ključne znake in simptome neželenih učinkov, povezanih z intravitrealnim injiciranjem, vključno z endoftalmitisom, povišanim intraokularnim tlakom, zatrganjem pigmentnega epitelija mrežnice in katarakto
It is estimated that after intravitreal administration of 2 mg to patients, the mean maximum plasma concentration of free aflibercept is more than 100-fold lower than the concentration of aflibercept required to half-maximally bind systemic VEGF (2.91 microgram/ml) in a study of healthy volunteers. 
V študiji z zdravimi prostovoljci so ocenili, da je po intravitrealnem odmerku 2 mg aflibercepta povprečna največja koncentracija prostega aflibercepta v plazmi več kot 100-krat nižja kot koncentracija aflibercepta, potrebna za vezavo polovice sistemskega VEGF (2,91 mikrogramov/ml).
One pre-filled syringe contains 90 microlitres, equivalent to 3.6 mg aflibercept. 
Ena napolnjena injekcijska brizga vsebuje 90 mikrolitrov raztopine, kar ustreza 3,6 mg aflibercepta.
The primary efficacy endpoint was mean change in BCVA from baseline to week 52. 
Primarni cilj učinkovitosti je bila povprečna sprememba BCVA od izhodiščne vrednosti do 52. tedna.
Efficacy Outcome 
Izid učinkovitosti
Diabetic macular oedema (DME) 
Diabetični makularni edem (DME)
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT Single dose = 2 mg/50 microlitres Extractable content = 4 mg/100microlitres 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT enkratni odmerek = 2 mg/50 mikrolitrov vsebnost viale = 4 mg/100 mikrolitrov
SPECIAL STORAGE CONDITIONS Store in refrigerator (2°C to 8°C). 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v hladilniku (2 ºC - 8 ºC).
The vial is for single use in one eye only. 
Ena viala je samo za enkratno uporabo v enem očesu.
Final study report submission: 
predložitev končnega poročila o študiji: november
At the 0.1 mg/kg dose, the systemic exposures based on Cmax and cumulative AUC for free aflibercept were approximately 17- and 10-fold higher, respectively, when compared to corresponding values observed in humans after an intravitreal dose of 2 mg. 
Pri odmerku 0,1 mg/kg je bila sistemska izpostavljenost prostemu afliberceptu glede na Cmax približno 17-krat oziroma glede na kumulativni AUC približno 10-krat večja v primerjavi z ustreznimi vrednostmi, ki so jih opazili pri ljudeh po intravitrealnem odmerku 2 mg.
The macula is the portion of retina responsible for fine vision. 
Rumena pega je del mrežnice, odgovorna za ostrino vida.
In a pharmacokinetic sub-study in 6 neovascular wet AMD patients with frequent sampling, maximum plasma concentrations of free aflibercept (systemic Cmax) were low, with a mean of approximately 0.02 microgram/ml (range 0 to 0.054) within 1 to 3 days after a 2 mg intravitreal injection, and were undetectable two weeks following dosage in almost all patients. 
V farmakokinetični podštudiji pri 6 bolnikih z neovaskularno vlažno AMD, ki so jim pogosto jemali vzorce krvi, so bile največje plazemske koncentracije prostega aflibercepta (sistemski Cmax) majhne, v povprečju približno 0,02 mikrograma/ml (v razponu od 0 do 0,054) v 1 do 3 dneh po intravitrealnem odmerku 2 mg.